Dr Reddy's Laboratories has expanded strategic collaboration with Amgen , one of the world's leading independent biotechnology companies, to market and distribute three of Amgen's medicines in India in the therapy areas of oncology and osteoporosis. Under the terms of the collaboration, the company will commercialise XGEVA'(denosumab), Vectibix' (panitumumab) and Prolia (donosumab) in India.
The BSE group 'A' stock of face value Rs . 5 has touched a 52 week high of Rs . 4382.95 on 20-Oct-2015 and a 52 week low of Rs . 2750 .00 on 21-Jan-2016.
The promoters holding in the company stood at 26.37%, while institutions and non-institutions held 41.16% and 15.64% respectively.
Dr . Reddy’s Laboratories has been listed as an Index component of the Dow Jones Sustainability Indices (DJSI) 2016 in the Pharmaceuticals, Biotechnology & Life Sciences Industry Group. The pharma major has been recognized for its corporate sustainability leadership and is the only pharmaceutical company on the Index of Emerging Markets.
The listing was based on 22 criterion, with Dr . Reddy’s receiving high scores for Product Quality and Recall Management, Codes of Business Conduct, Environmental Reporting, Corporate Citizenship and Philanthropy.